Performance & GH axis
Tesamorelin
GHRH Analog
A growth hormone releasing hormone (GHRH) analog FDA-approved for reducing excess abdominal fat in HIV patients. Also studied for cognitive benefits and body composition improvement.
Also known as: Egrifta, TH9507
- Status
- Tesamorelin is approved by the U.S. FDA and has official prescribing information.
- Evidence
- Approved labeling. Official prescribing information exists, based on clinical trials in people.
- Half-life
- ~26 minutes (but effects are prolonged)
- How it's taken
- Daily subcutaneous injection
- Mechanism
- Growth-hormone secretagogue
- Pathways
- GHRH analogue, GH axis
How Tesamorelin works
Stimulates the pituitary gland to produce and release growth hormone in a natural pulsatile pattern. This increases lipolysis (fat breakdown), particularly in visceral abdominal fat.
What research has looked at
- Targeted visceral fat reduction
- Improved body composition
- May improve cognitive function
- Natural GH release pattern
- Reduced liver fat
Evidence level: Approved labeling. Official prescribing information exists, based on clinical trials in people. These are areas studied or reported, not promised effects.
Reported side effects and risks
- Injection site reactions (redness, swelling)
- Joint pain
- Muscle pain
- Swelling in extremities
- Increased blood sugar
- Numbness or tingling
Sources
- FDA approved-drug listing for tesamorelin · U.S. Food & Drug Administration
- DailyMed prescribing information for tesamorelin · NIH · DailyMed
- PubMed research on tesamorelin HIV lipodystrophy · NIH · National Library of Medicine
- DrugBank record for tesamorelin · DrugBank
Track Tesamorelin in Peptide Vault
Log every dose, set reminders on your own schedule, rotate injection sites and keep your vials organized. Peptide Vault records what you enter. It doesn't recommend compounds or doses. iPhone, on-device.
Related compounds
Tesamorelin FAQ
What is Tesamorelin?
A growth hormone releasing hormone (GHRH) analog FDA-approved for reducing excess abdominal fat in HIV patients. Also studied for cognitive benefits and body composition improvement.
How does Tesamorelin work?
Stimulates the pituitary gland to produce and release growth hormone in a natural pulsatile pattern. This increases lipolysis (fat breakdown), particularly in visceral abdominal fat.
Is Tesamorelin FDA approved?
Yes. Tesamorelin is approved by the U.S. FDA and has official prescribing information. Evidence level: approved labeling. Official prescribing information exists, based on clinical trials in people.
What is the half-life of Tesamorelin?
Reported half-life: ~26 minutes (but effects are prolonged).
How is Tesamorelin taken?
Daily subcutaneous injection.
What side effects have been reported with Tesamorelin?
Reported in the sources: Injection site reactions (redness, swelling); Joint pain; Muscle pain; Swelling in extremities; Increased blood sugar; Numbness or tingling.
Educational summary compiled from the sources listed above. Not medical advice. Peptide Vault does not sell, source or recommend any compound. Talk to a qualified clinician before starting or changing anything.